JP2012508753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508753A5 JP2012508753A5 JP2011536450A JP2011536450A JP2012508753A5 JP 2012508753 A5 JP2012508753 A5 JP 2012508753A5 JP 2011536450 A JP2011536450 A JP 2011536450A JP 2011536450 A JP2011536450 A JP 2011536450A JP 2012508753 A5 JP2012508753 A5 JP 2012508753A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- peptide
- peptide immunogen
- item
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 230000002163 immunogen Effects 0.000 claims description 55
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims description 6
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 6
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 4
- 108010049048 Cholera Toxin Proteins 0.000 claims description 4
- 102000009016 Cholera Toxin Human genes 0.000 claims description 4
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 4
- -1 aminoalkyl glucosan phosphate compound Chemical class 0.000 claims description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 241000304886 Bacilli Species 0.000 claims description 2
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 108010059574 C5a peptidase Proteins 0.000 claims description 2
- 241000272470 Circus Species 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 102000009843 Thyroglobulin Human genes 0.000 claims description 2
- 108010034949 Thyroglobulin Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940076156 streptococcus pyogenes Drugs 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 229960002175 thyroglobulin Drugs 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11388008P | 2008-11-12 | 2008-11-12 | |
| US61/113,880 | 2008-11-12 | ||
| PCT/US2009/064115 WO2010056796A1 (en) | 2008-11-12 | 2009-11-12 | Human m2e peptide immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014106974A Division JP2014148549A (ja) | 2008-11-12 | 2014-05-23 | ヒトＭ２ｅペプチド免疫原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508753A JP2012508753A (ja) | 2012-04-12 |
| JP2012508753A5 true JP2012508753A5 (https=) | 2013-04-25 |
| JP5693460B2 JP5693460B2 (ja) | 2015-04-01 |
Family
ID=41682556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536450A Expired - Fee Related JP5693460B2 (ja) | 2008-11-12 | 2009-11-12 | ヒトＭ２ｅペプチド免疫原 |
| JP2014106974A Pending JP2014148549A (ja) | 2008-11-12 | 2014-05-23 | ヒトＭ２ｅペプチド免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014106974A Pending JP2014148549A (ja) | 2008-11-12 | 2014-05-23 | ヒトＭ２ｅペプチド免疫原 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8329188B2 (https=) |
| EP (1) | EP2346529B1 (https=) |
| JP (2) | JP5693460B2 (https=) |
| AU (1) | AU2009314091B2 (https=) |
| CA (1) | CA2743306A1 (https=) |
| TW (1) | TW201029663A (https=) |
| WO (1) | WO2010056796A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP2346529B1 (en) * | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
| US8974788B2 (en) * | 2009-08-14 | 2015-03-10 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| US9493514B2 (en) * | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| WO2013112916A1 (en) * | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| KR20230037502A (ko) * | 2020-05-20 | 2023-03-16 | 바이사이클티엑스 리미티드 | 넥틴-4에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
| US4102877A (en) | 1976-07-28 | 1978-07-25 | Merck & Co., Inc. | Cyclization of peptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| ATE378066T1 (de) | 1998-09-30 | 2007-11-15 | Wyeth Corp | Mutiertes cholera holotoxin als hilfsmittel |
| CA2449670A1 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| KR100898648B1 (ko) | 2001-06-07 | 2009-05-22 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
| US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| EP1819732A2 (en) * | 2004-12-06 | 2007-08-22 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| US8642513B2 (en) * | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
| NZ585500A (en) * | 2007-11-12 | 2012-06-29 | Theraclone Sciences Inc | Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus |
| EP2346529B1 (en) * | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
-
2009
- 2009-11-12 EP EP09752676.8A patent/EP2346529B1/en not_active Not-in-force
- 2009-11-12 TW TW98138409A patent/TW201029663A/zh unknown
- 2009-11-12 US US12/617,243 patent/US8329188B2/en not_active Expired - Fee Related
- 2009-11-12 CA CA 2743306 patent/CA2743306A1/en not_active Abandoned
- 2009-11-12 JP JP2011536450A patent/JP5693460B2/ja not_active Expired - Fee Related
- 2009-11-12 WO PCT/US2009/064115 patent/WO2010056796A1/en not_active Ceased
- 2009-11-12 AU AU2009314091A patent/AU2009314091B2/en not_active Ceased
-
2012
- 2012-06-14 US US13/523,710 patent/US8932597B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014106974A patent/JP2014148549A/ja active Pending
-
2015
- 2015-01-12 US US14/594,461 patent/US20150125423A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508753A5 (https=) | ||
| WO2020249756A1 (en) | Fusion proteins for tuberculosis vaccines | |
| JP2010508276A5 (https=) | ||
| CN104507496B (zh) | 包含与crm197载体蛋白偶联的hiv gp41肽的免疫原性化合物 | |
| JP2020534874A (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| JP2015529677A5 (https=) | ||
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| CN103561762A (zh) | 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法 | |
| US20080095792A1 (en) | Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus | |
| US9943582B2 (en) | Cholera toxin chimera and its use as a staph vaccine | |
| CN106692963B (zh) | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 | |
| JP2008500043A (ja) | 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド | |
| US9950050B2 (en) | Vaccines based on hepatitis B core antigens | |
| CN115850398B (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
| US20220054615A1 (en) | Pertussis booster vaccine | |
| Del Giudice | In vivo carrier effect of heat shock proteins in conjugated vaccine constructs | |
| EP0536352B1 (en) | Therapeutic and preventive vaccines for hiv | |
| JP2021505525A5 (https=) | ||
| US20180071384A1 (en) | Vaccines based on hepatitis b core antigens | |
| CN111948387B (zh) | 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用 | |
| US12409214B2 (en) | Immunogenic antigens | |
| CN111948399A (zh) | 结核分枝杆菌抗原蛋白Rv1705c及其T细胞表位肽的应用 | |
| JP2020537488A5 (https=) | ||
| JP2015525771A5 (https=) | ||
| US20230226166A1 (en) | Immunogenic Antigens |